<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371344</url>
  </required_header>
  <id_info>
    <org_study_id>F506-CL-0404</org_study_id>
    <secondary_id>2009-012259-21</secondary_id>
    <nct_id>NCT01371344</nct_id>
  </id_info>
  <brief_title>A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients</brief_title>
  <acronym>PROGRESSION</acronym>
  <official_title>A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in Paediatric Solid Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study, a follow up to study FG506-CL-0403, is to see how safe and
      effective Modigraf® is (Part A) and to see how safe and effective it is to change your
      child's medication from Modigraf® to Prograf® (Part B).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To monitor the safety and efficacy of Modigraf® (tacrolimus granules) in stable paediatric
      allograft recipients (Part A) and to monitor dose changes and tacrolimus whole blood trough
      levels after conversion from a Modigraf based Immunosuppression regimen to a Prograf® based
      Immunosuppression regimen (Part B).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial will not complete until at least 2025 and evolution of immunosuppressant therapy has made
    it unlikely that patients will convert from Modigraf to Prograf.
  </why_stopped>
  <start_date type="Actual">June 24, 2011</start_date>
  <completion_date type="Actual">March 28, 2017</completion_date>
  <primary_completion_date type="Actual">March 28, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rejection episodes</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Evaluation for Part A of Study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Evaluation for Part A of Study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Evaluation for Part A of Study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tacrolimus whole blood trough levels after conversion from Modigraf to Prograf</measure>
    <time_frame>day 1, day 2, day 3-16, day 30</time_frame>
    <description>Evaluation for Part B of Study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of dose changes</measure>
    <time_frame>Through 30 days</time_frame>
    <description>Evaluation for Part B of Study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of safety through the monitoring of Adverse Events, laboratory parameters</measure>
    <time_frame>Up to 12 months for Part A; Up to 30 days for Part B</time_frame>
    <description>Evaluation for both Part A and Part B of Study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Heart Transplantation</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Tacrolimus granules Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus granules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus granules Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus granules converted to Tacrolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus granules</intervention_name>
    <description>oral</description>
    <arm_group_label>Tacrolimus granules Part B</arm_group_label>
    <arm_group_label>Tacrolimus granules Part A</arm_group_label>
    <other_name>Modigraf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>oral</description>
    <arm_group_label>Tacrolimus granules Part B</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        F506-CL-0404 Part A

          -  Subject was ≤12 years of age at enrolment into study F506-CL-0403

          -  Subject received at least one dose of Modigraf in the F506-CL-0403 study

        F506-CL-0404 Part B

          -  Subject received at least one dose of Modigraf in the F506-CL-0403 study

          -  Subject participated in F506-CL-0404 Part A

          -  Subject has continuously been dosed with Twice daily (BID) Modigraf since the End of
             Study Visit for Part A (ESVA) from F506-CL-0404 Part A

          -  Subject is stable and has had no dose changes in the preceding 2 weeks

        Exclusion Criteria:

        F506-CL-0404 Part A

          -  As all subjects included in this study conform to the exclusion criteria in study
             F506-CL-0403, hence no specific exclusion criteria are relevant for this study

        F506-CL-0404 Part B

          -  There are no specific exclusion criteria for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Study Manager</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site BE40 Clinique Univ. Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR60 Groupement Hospitalier EST</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR61 Hopital Robert Debre</name>
      <address>
        <city>Paris Cedex 19</city>
        <zip>75945</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE31 Kliniken der Medizinischen Hoc</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE30 Universitätsklin Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL50 Centrum Zdrowia Dziecka</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES22 H.U. Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES20 Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES21 Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES23 Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB14 Alder Hey Children Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB13 Cent. Manchester Uni. Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Transplantation</keyword>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Heart Transplantation</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

